Online inquiry

IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3590MR)

This product GTTS-WQ3590MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LYPD3 gene. The antibody can be applied in Neoplasms research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_014400.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27076
UniProt ID O95274
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3590MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15575MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ10503MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ14252MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG-7116
GTTS-WQ15624MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VAY-736
GTTS-WQ5710MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ10942MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MBG-453
GTTS-WQ5878MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ14975MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SHR-1314
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW